文献速递核素与放射性配体治疗肿瘤 PET/CT

新型订书肽MDM2/X-p53拮抗剂PM2增强177Lu标记抗CD44v6抗体AbN44v6对三维多细胞肿瘤球体的体外靶向放射核素治疗效应

Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2.
PubMed 文献 · EJNMMI Res · 2020-04-16

本研究在两种野生型p53细胞系(HCT116结直肠癌与UM-SCC-74B头颈鳞癌)来源的三维多细胞肿瘤球体中,评估了新型订书肽MDM2/X-p53拮抗剂PM2对177Lu标记抗CD44v6抗体AbN44v6靶向放射核素治疗(TRNT)的增效作用。结果显示177Lu-AbN44v6以剂量依赖和抗原依赖方式抑制球体生长,20 μM PM2单药即显著抑制球体生长,两者联合比任一单药均显著更强。

要点

  • 177Lu-AbN44v6以剂量依赖和抗原依赖方式抑制两种细胞系球体生长。
  • 20 μM PM2单药显著抑制两种球体模型生长。
  • TRNT联合PM2比任一单药显著更强,HCT116球体联合组生长速率较单药降低两至三倍。

核心结论

  • 177Lu-AbN44v6的TRNT以剂量依赖和抗原依赖方式有效抑制球体生长,PM2单药具有生长抑制作用。
  • TRNT与PM2联合在三维多细胞肿瘤球体模型中增强了TRNT的治疗效应,该概念验证研究展示了靶向CD44v6的TRNT与PM2联合的潜力与可能性。

研究设计与样本

  • 体外研究,使用两种野生型p53细胞系:HCT116(结直肠癌)和UM-SCC-74B(头颈鳞状细胞癌),表达不同水平的靶抗原CD44v6。
  • 先在二维细胞实验中验证177Lu-AbN44v6的抗原特异性结合,再用蛋白质印迹评估未标记AbN44v6对Erk1/2下游磷酸化的影响。
  • 在三维多细胞肿瘤球体实验中评估未标记AbN44v6、177Lu-AbN44v6、PM2或联合(标记/未标记AbN44v6±PM2)的治疗效果。

主要发现

  • 放射性标记抗体在两种细胞系上均特异性结合CD44v6。
  • 未标记AbN44v6在所有测试浓度下均未诱导Erk1/2下游磷酸化,重复使用未标记抗体未导致任何球体生长抑制。
  • 177Lu-AbN44v6以剂量依赖和抗原依赖方式损害球体生长。
  • 20 μM PM2单药显著损害两种球体模型的球体生长。
  • TRNT与PM2联合比任一单药显著更强;HCT116球体中,PM2联合100 kBq 177Lu-AbN44v6在治疗后14天较单药使球体生长速率降低两至三倍;UM-SCC-74B球体中,联合治疗在治疗后10天使球体尺寸较初始尺寸缩小。

关键数值与推荐

  • 未标记AbN44v6在所有测试浓度下均未诱导Erk1/2下游磷酸化,重复治疗未导致球体生长抑制。
  • PM2单药剂量为20 μM时显著损害两种球体模型生长。
  • HCT116球体中,PM2联合100 kBq 177Lu-AbN44v6在治疗后14天较单药使球体生长速率降低两至三倍。
  • UM-SCC-74B球体中,联合治疗在治疗后10天使球体尺寸较初始尺寸缩小。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Precision therapeutics continuously make advances in cancer therapy, and a field of growing interest is the combination of targeted radionuclide therapy (TRNT) with potential radiosensitizing agents. This study evaluated whether the effects of in vitro TRNT, using the 177Lu-labeled anti-CD44v6 antibody AbN44v6, were potentiated by the novel stapled MDM2/X-p53 antagonist PM2. MATERIALS AND METHODS: Two wt p53 cell lines, HCT116 (colorectal carcinoma) and UM-SCC-74B (head and neck squamous cell carcinoma), expressing different levels of the target antigen, CD44v6, were used. Antigen-specific binding of 177Lu-AbN44v6 was initially verified in a 2D cell assay, after which the potential effects of unlabeled AbN44v6 on downstream phosphorylation of Erk1/2 were evaluated by western blotting. Further, the therapeutic effects of unlabeled AbN44v6, 177Lu-AbN44v6, PM2, or a combination (labeled/unlabeled AbN44v6 +/- PM2) were assessed in 3D multicellular tumor spheroid assays. RESULTS: Radiolabeled antibody bound specifically to CD44v6 on both cell lines. Unlabeled AbN44v6 binding did not induce downstream phosphorylation of Erk1/2 at any of the concentrations tested, and repeated treatments with the unlabeled antibody did not result in any spheroid growth inhibition. 177Lu-AbN44v6 impaired spheroid growth in a dose-dependent and antigen-dependent manner. A single modality treatment with 20 μM of PM2 significantly impaired spheroid growth in both spheroid models. Furthermore, the combination of TRNT and PM2-based therapy proved significantly more potent than either monotherapy. In HCT116 spheroids, this resulted in a two- and threefold spheroid growth rate decrease for the combination of PM2 and 100 kBq 177Lu-AbN44v6 compared to monotherapies 14-day post treatment. In UM-SCC-74B spheroids, the combination therapy resulted in a reduction in spheroid size compared to the initial spheroid size 10-day post treatment. CONCLUSION: TRNT using 177Lu-AbN44v6 proved efficient in stalling spheroid growth in a dose-dependent and antigen-dependent manner, and PM2 treatment demonstrated a growth inhibitory effect as a monotherapy. Moreover, by combining TRNT with PM2-based therapy, therapeutic effects of TRNT were potentiated in a 3D multicellular tumor spheroid model. This proof-of-concept study exemplifies the strength and possibility of combining TRNT targeting CD44v6 with PM2-based therapy.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Mortensen ACL, Morin E, Brown CJ, et al. Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2. EJNMMI Res. 2020. PMID: 32300907. doi:10.1186/s13550-020-0613-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。